We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+34.07%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$104M
AUM Growth
+$15M
Cap. Flow
+$2.81M
Cap. Flow %
2.71%
Top 10 Hldgs %
90.98%
Holding
49
New
9
Increased
23
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
MTEM
Molecular Templates, Inc.
MTEM
+$4.49M
2
SCYX icon
SCYNEXIS
SCYX
+$3.72M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$1.33M
4
CLMT icon
Calumet Specialty Products
CLMT
+$361K
5
CDLX icon
Cardlytics
CDLX
+$273K

Top Sells

Rank Stock Value
1
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$3.01M
2
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$1.94M
3
CACC icon
Credit Acceptance
CACC
+$238K
4
EXPE icon
Expedia Group
EXPE
+$237K
5
FWONK icon
Liberty Media Series C
FWONK
+$224K

Sector Composition

Rank Sector Weight
1 Healthcare 73.43%
2 Financials 1.71%
3 Consumer Discretionary 1.29%
4 Communication Services 1.15%
5 Industrials 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
1
DELISTED
Molecular Templates, Inc.
MTEM
$29.3M 28.23%
139,533
+31,250
+29% +$4.49M
SBBP
2
DELISTED
Strongbridge Biopharma plc.
SBBP
$13.8M 13.33%
6,612,065
– –
STSA
3
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$13M 12.51%
659,252
-211,568
-24% -$3.01M
ABDC
4
DELISTED
Alcentra Capital Corp
ABDC
$9.1M 8.77%
1,005,000
+5,000
+0.5% +$44.9K
SCYX icon
5
SCYNEXIS
SCYX
$44.5M
$7.22M 6.97%
99,201
+45,138
+83% +$3.72M
GARS
6
DELISTED
Garrison Capital Inc.
GARS
$7.12M 6.87%
1,223,096
– –
KALA icon
7
KALA BIO
KALA
$15.7M
$5.47M 5.28%
594
– –
SPY icon
8
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$4.51M 4.35%
14,010
– –
VIRX
9
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.75M 2.65%
232,426
+79,688
+52% +$1.33M
LITS
10
Lite Strategy Inc
LITS
$33M
$2.1M 2.02%
42,278
– –
EIGR
11
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$925K 0.89%
2,070
+3
+0.1% +$1.06K
FSK icon
12
FS KKR Capital
FSK
$3.11B
$684K 0.66%
27,913
+7,843
+39% +$187K
CLMT icon
13
Calumet Specialty Products
CLMT
$3.58B
$621K 0.6%
170,149
+104,460
+159% +$361K
CTIC
14
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$514K 0.5%
325,610
+425
+0.1% +$403
CDLX icon
15
Cardlytics
CDLX
$24M
$352K 0.34%
+559
New +$273K
ASMB icon
16
Assembly Biosciences
ASMB
$512M
$340K 0.33%
+1,385
New +$255K
ARQL
17
DELISTED
Arqule Inc
ARQL
$310K 0.3%
+15,522
New +$180K
CHTR icon
18
Charter Communications
CHTR
$16.4B
$309K 0.3%
638
+3
+0.5% +$1.38K
KURA icon
19
Kura Oncology
KURA
$967M
$307K 0.3%
22,295
-9,272
-29% -$137K
TDG icon
20
TransDigm Group
TDG
$68.9B
$290K 0.28%
518
+2
+0.4% +$1.09K
MA icon
21
Mastercard
MA
$487B
$286K 0.28%
959
+3
+0.3% +$846
MELI icon
22
Mercado Libre
MELI
$94.2B
$285K 0.27%
498
+2
+0.4% +$1.11K
MCO icon
23
Moody's
MCO
$90.7B
$280K 0.27%
1,179
+4
+0.3% +$889
AMT icon
24
American Tower
AMT
$78.7B
$279K 0.27%
1,214
+4
+0.3% +$871
V icon
25
Visa
V
$694B
$276K 0.27%
1,470
+5
+0.3% +$901
1
2

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q4 2019 Portfolio in Review

As of Q4 2019, Caxton Corporation held 49 positions worth $104M, up 17% from $88.7M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Caxton Corporation's Q4 2019 filing shows 9 new, 23 increased, 3 reduced and 9 closed positions. Its largest new stake was Cardlytics: 559 shares worth $352K. The largest sale was Satsuma Pharmaceuticals, Inc. Common Stock, an estimated $3.01M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 64% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Caxton Corporation's largest Q4 2019 buy was Cardlytics: 559 shares worth $352K.
  • Caxton Corporation added most to Molecular Templates, Inc. in Q4 2019, an estimated $4.49M increase.
  • Caxton Corporation's biggest Q4 2019 reduction was Satsuma Pharmaceuticals, Inc. Common Stock, cutting an estimated $3.01M.
  • Caxton Corporation fully exited Berkshire Hathaway Class B in Q4 2019, selling an estimated $1.94M.
  • Caxton Corporation's ten largest holdings make up 91% of its $104M portfolio in Q4 2019.
  • Caxton Corporation opened 9 new positions and closed 9 in Q4 2019.
  • Caxton Corporation's portfolio value rose 17% quarter-over-quarter to $104M.

Based on Caxton Corporation's 13F filing for Q4 2019, filed 14 Feb 2020.